Management of Urinary Incontinence in the Elderly

First-Line Treatment: Behavioral Interventions

Behavioral therapy should always be attempted before medications in elderly patients because it is highly effective and carries no adverse effects—a critical consideration in this population prone to polypharmacy and drug-related complications 1
For stress incontinence, Pelvic floor muscle training (PFMT) as monotherapy is recommended (Grade: strong recommendation, high-quality evidence) 1
For urgency incontinence, Bladder training is recommended (Grade: strong recommendation, moderate-quality evidence) 1
For mixed incontinence, PFMT combined with bladder training is recommended (Grade: strong recommendation, moderate-quality evidence) 1

The American College of Physicians recommends against systemic pharmacologic therapy for stress incontinence (Grade: strong recommendation) 1
Mirabegron is an excellent choice for elderly patients due to its similar efficacy to antimuscarinics with a relatively lower adverse effect profile 2
Tolterodine is the best antimuscarinic option when one is needed because it has discontinuation rates due to adverse effects similar to placebo 1
Solifenacin is an acceptable alternative with the lowest discontinuation rate among antimuscarinics that show higher rates than placebo (NNTH 78) 1
Oxybutynin should be avoided as it has the highest discontinuation rate due to adverse effects (NNTH 16) and is associated with increased risk of hallucinations, dry mouth, constipation, and cognitive impairment 1

Use extreme caution when prescribing any incontinence medication to frail elderly patients, as these medications have a lower therapeutic index and higher adverse event profile in this population 2
Always calculate creatinine clearance using the Cockcroft-Gault equation—do not rely on serum creatinine alone, as this leads to inappropriate dosing in elderly patients 2

Initiate type-appropriate behavioral therapy for 8-12 weeks 1, 2
If behavioral therapy fails for urgency incontinence: Add mirabegron or tolterodine, with dose adjustment based on calculated creatinine clearance 1, 2
Trial medication for 4-8 weeks before judging efficacy 2
If first medication fails: Consider dose modification, switching to the beta-3 agonist (mirabegron) if started on an antimuscarinic, or trying an alternative antimuscarinic 2
Refer to specialist if refractory to both behavioral and pharmacologic therapy 2

Never prescribe antimuscarinics for stress incontinence—they are ineffective and expose patients to unnecessary adverse effects 1
Do not skip behavioral therapy and proceed directly to medications—behavioral interventions are more effective and safer 1

Elderly patients often have atypical presentations of urinary incontinence, including confusion, functional decline, or falls, rather than classic urinary symptoms, according to the European Urology guidelines 3
Annual screening for urinary incontinence is essential, as patients rarely volunteer this information, as recommended by the Journal of the American Geriatrics Society (JAGS) 4

Polypharmacy interactions are common in the elderly population, and anticholinergics can increase the risk of cognitive impairment and confusion, as noted in European Urology 3

Calculating creatinine clearance is crucial in elderly patients, as it affects the dosing of medications such as mirabegron, which requires dose adjustment in severe renal impairment, as stated in Praxis Medical Insights: Practical Summaries of Clinical Guidelines 5

Evaluating and treating urinary tract infections, polyuria from uncontrolled diabetes, fecal impaction, atrophic vaginitis, and restricted mobility can help address urinary incontinence, as recommended by the Journal of the American Geriatrics Society (JAGS) 4
The American Geriatrics Society recommends treating urinary tract infections, but not asymptomatic bacteriuria, which occurs in 15-50% of elderly patients, as stated in Praxis Medical Insights: Practical Summaries of Clinical Guidelines 6

Reassessing renal function periodically is necessary due to the risk of polypharmacy, and considering drug interactions with other medications is crucial, as noted in European Urology 3